Kornimate/medical-research-clean huggingface dataset:
outcomes of delivery in patients with dyspareunia

Conditions: Dyspareunia; Pregnancy; Provoked Vestibulodynia; Pelvic Floor Dysfunction

Summary: the focus of this pilot study is to determine if a woman who experiences pain during sexual intercourse has a higher risk of complications during labor and delivery secondary to pelvic floor dysfunction, anxiety and intolerance towards pelvic examinations. furthermore, it is unclear whether women with prepartum dyspareunia experience an improvement following vaginal delivery. while physicians may expect that vaginal birth improves dyspareunia due to the stretching effect on pelvic floor, to date, there is insufficient evidence to support this claim. the investigators plan to prospectively study 200 patients at our institution, collect information regarding birth and follow them, via questionnaires, regarding their dyspareunia postpartum.


Eligibility criteria:
inclusion criteria: 1. 200 nulliparous women admitted to the labor and delivery department at the hadassah medical center, above the age of 18. 2. able and willing to read, understand, and sign the informed consent form and questionnaire. 3. agree to be contacted in the future to complete telephone questionnaires. exclusion criteria: 1. induction of labor 2. placental abruption, placenta previa 3. malpresentation 4. non reassuring fetal heart rate upon admission 5. any other contraindication for vaginal delivery 6. multifetal pregnancy
function and imaging assessments for g1961e-associated stargardt disease

Conditions: Stargardt Disease; Stargardt Disease 1; Fundus Flavimaculatus; Macular Degeneration, Stargardt; Macular Dystrophy With Flecks, Type 1

Summary: some phenotypes of stargardt disease are rather distinct. this includes the 'bull's eye maculopathy' phenotype associated with the frequent abca4 g1961e variant. in anticipation of a treatment trial, this natural history study aims to compare functional and structural outcome measures systematically.


Eligibility criteria:
inclusion criteria: * adult patients with g1961e-associated stargardt disease * defined by (1.) the presence of two pathogenic abca4 variants with at least one abca4g1961e variant, (2.) a stargardt disease phenotype, and (3.) the absence of pathogenic variants in prph2, prom1, and elovl4 exclusion criteria: * inability to give informed consent * prior surgery (other than anti-vegf injections, cataract surgery, yag laser capsulotomy, or laser retinopexy) that - according to the investigator's judgment - may affect visual function assessments (e.g., retinal detachment surgery, glaucoma filtration surgery, or a history of a corneal transplant in the study-eye) * concurrent ophthalmic conditions in the study eye that (according to the investigator's judgment) may contribute to loss of vision such as clinically significant opacification of the ocular media (corneal dystrophies, cataract), other retinal diseases, or disease of the optic nerve head and visual pathway (including amblyopia) * major surgery planned or other events that (according to the investigator's judgment) could hinder follow-up examinations (e.g., knee replacement)

Keywords: stargardt disease stgd1 p.gly1961glu g1961e c.5882g>a
salvage treatment with glofitamab in r/r b-nhl: a gimema-fil study

Conditions: B-cell Non Hodgkin Lymphoma; Relapse; Refractory Lymphoma

Summary: the goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the compassionate use program, in relapsed/refractory b-nhl patients. the main question it aims to answer is the rate of patients in complete response.

this is an observational multicenter study aimed at assessing the anti-lymphoma activity of glofitamab in relapsed/refractory b cell non-hodgikin lymphoma patients treated according to the compassionate use program in italy between march 2022 and september 2023. patients will be observed for a minimum of 12 months after the last glofitamab administration.

Eligibility criteria:
inclusion criteria: 1. patients who received glofitamab according to compassionate use program ag42296 2. age \> 18 years 3. patients who received at least one dose of glofitamab between march 2022 and september 2023 in the context of the compassionate use program and who completed at least 1 year of observation after last glofitamab administration unless the patient died or was lost to follow up 4. patients who provided their consent according to local regulation to collect their data for study purposes, dead patients or patients lost to follow up for which any attempt has been made to collect their consent, according to local regulation on data privacy exclusion criteria: * none
study on the establishment of a system for early warning and prognostic evaluation of patients with heat stroke

Conditions: Heat Stroke; Early Waking; MODS; Proteinosis; Liver Injury; Kidney Injury

Summary: heat stroke is a clinical syndrome with high incidence and high fatality rate in summer. patients with liver, kidney, and brain damage are prone to secondary mods, and the prognosis is poor due to high medical costs. at present, there is no unified diagnostic criteria for acute liver injury associated with heat stroke, and the commonly used prognosis scores are rarely included in liver injury indicators, which is not good for practicality.

the project intends to collect the peripheral blood of the normal population, the 24 hours after the onset of heat stroke and the patients in the recovery period, to separate and extract plasma, pbmc, and plasma exosomal mirna, and sequence to search for indicators related to disease deterioration and prognosis, construct and verify the early warning and prognosis evaluation system of the disease. on this basis, the researcher explore cellular and molecular mediated pathological mechanisms of heat stroke, and then clarify the treatment target of heat stroke.

Eligibility criteria:
inclusion criteria: 1. the patient voluntarily signs an informed consent form; 2. adult patients who meet the criteria for heat stroke; 3. heat stroke is defined as heat stroke (heat stroke, hs) is a serious fatal disease caused by heat injury factors acting on the body, accompanied by multiple organ damage. exclusion criteria: 1. age \ 90 years old; 2. patients with advanced tumors, pregnancy or lactation; 3. patients who missed out during treatment and whose data are incomplete.
early diagnosis of leukemic children patients based on clinical, age estimation and radiographical evaluation of oral affection

Conditions: Leukemia

Summary: early diagnosis of leukemia which is malignant tumor affecting bone especially in children is import to allow early intervention improving prognosis. it is known that leukemic patients suffer from clinical signs as anemia, thrombocytopenia, and pronounced hepatosplenomegaly or lymphadenopathy. however, sometimes these clinical signs may be not clearly manifested and may look like anemia. the early diagnosis could be achieved through dentist by accessing clinical and radiographical signs such as oral masses, gingival bleeding /or enlargement and oral ulceration with radiographical features including focal or generalized osteolysis of bone with presence of moth eating appearance and even with abnormal teeth chronology regarding teeth morphology, germ formation of permanent teeth and their sequence of eruption. therefore, accessing of these special clinical and radiographical features by the dentist could help in early diagnosis of leukemic children patients

ten children patients suffer from leukemia selected after initial diagnosis from hematology unit of faculty of medicine, tanta university based on their clinical signs such as; bone pain, fatigability, lymph node enlargement...etc., with abnormal cbc revealing anemia or abnormal wbcs. these patients accessed clinically for oral signs and accessed radiographically using panoramic radiographs and cone beam computed tomography (cbct) to evaluate chronology and bone density.

Eligibility criteria:
inclusion criteria: 1-children will be aged from 6-10 years 2 children diagnosed with leukemia but they don't start treatment yet - exclusion criteria: 1. children below or above the age 2. children already diagnosed by leukemia and started treatment 3. children diagnosed by other bone lesions showing osteolytic bone or anemia as thalassemia or sickle cell anemia or any other bone pathology
effect of radioiodine therapy on ovarian reserve in female patients with differentiated thyroid cancer

Conditions: Ovarian Insufficiency; Radiation Exposure

Summary: thyroid carcinoma is the most common endocrine malignancy. surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (dtc), followed by radioiodine (rai) therapy if indicated. for women with dtc, the effects of rai therapy on gonadal and reproductive function are an important consideration. this study aimed to evaluate the effects of rai therapy on ovarian function.


Eligibility criteria:
inclusion criteria: * female patient in childbearing period. * female patient with differentiated thyroid carcinoma. * underwent thyroidectomy. * candidate for radioactive iodine therapy. exclusion criteria: * • male patients. * postmenopausal female patients. * female patients with undifferentiated thyroid carcinoma. * pregnant female patients. * lactating female patients.
laparoscopic versus vaginal hysterectomy in women with abnormal uterine bleeding using bipolar vessel sealer

Conditions: Uterine Bleeding

Summary: this study will be a randomized clinical trial to evaluate the surgical performance and outcome of total laparoscopic hysterectomy compared to non-descent vaginal hysterectomy ,using bipolar vessel sealer,in cases of abnormal uterine bleeding in mansoura university hospital in order to reach the optimum technique for our locality

hysterectomy is the surgical removal of the uterus. it is the commonest major gynecological surgery, next to caesarean section, with millions of procedures performed annually throughout the world.approximately 90% of hysterectomies are performed for benign conditions. although there are many approaches to hysterectomy, which depend on clinical criteria, certain patients may be eligible to be operated in any of the several available approaches. the optimal route of hysterectomy for a patient will depend on the pathological nature, size and shape of the vagina and uterus, uterine descent, endometriosis and the likelihood of pelvic adhesions, adnexal masses, previous pelvic surgery, available hospital technology, devices and the surgeon's preference. approaches to hysterectomy may be broadly categorized into four options: abdominal hysterectomy (ah); vaginal hysterectomy (vh); laparoscopic hysterectomy (lh) where at least some of the operation is conducted laparoscopically and robotic-assisted hysterectomy (rh).vaginal and laparoscopic procedures are considered "minimally invasive" surgical approaches because they do not require a large abdominal incision and, thus, typically are associated with shortened hospitalization and postoperative recovery times compared with open abdominal hysterectomy. this study will be a randomized clinical trial to evaluate the surgical performance and outcome of total laparoscopic hysterectomy compared to non-descent vaginal hysterectomy, using bipolar vessel sealer, in cases of abnormal uterine bleeding in order to reach the optimum technique with lower cost to be easily applied to low resource settings.

Eligibility criteria:
inclusion criteria: * women assigned for performing hysterectomy for abnormal uterine bleeding due to benign pathology. * uterine size by bimanual examination ≤14 weeks gestational size. * cases with uterine volumes ≤ 400cm3 will be included in this study. exclusion criteria: * patients with bmi \> 30kg/m2 * uteri \> 14 weeks gestational size by bimanual examination or volume \> 400cm3 * women with positive pap smear for cin or endometrial biopsy with atypia or carcinoma. * patient with other known body malignancy. * patient with other pelvic pathology, endometriosis or pelvic abscesses. * patients with abdominal scars.

Keywords: vaginal hysterectomy laparoscopic hysterectomy
dm-imt - controlled, randomized, three-arm intervention study on the safety and efficacy of regular respiratory muscle training in patients with myotonic dystrophy type 1

Conditions: Myotonic Dystrophy 1

Summary: for some diseases, regular respiratory muscle training could delay the start of ventilation. for dm1, however, there are no clinically high-quality studies. only a case description from the year 2006 showed a missing improvement of the symptoms after respiratory muscle training in one patient, accordingly there are no recommendations in this issue. within the scope of this monocentric, three-arm, controlled intervention study, 45 patients with genetically confirmed type 1 myotonic dystrophy will be randomized in three groups of 15 patients each, age-, gender- and symptom-corrected by the muscular impairment rating scale (mirs). the dm1 patients will receive regular respiratory muscle training for a period of 9 months. the aim of this study is to evaluate the safety and effectiveness of regular inspiratory strength-breathing muscle training on 15 patients, the safety and effectiveness of regular inspiratory endurance respiratory muscle training on 15 patients, and the comparison to the natural course in 15 patients without training. subsequently, we will provide treatment recommendations for respiratory training in dm1.


Eligibility criteria:
inclusion criteria: * the patient is willing and able to provide a signed informed consent form * the patient is ≥ 18 years old * the diagnosis of type 1 myotonic dystrophy has been confirmed by molecular genetics * the patient is able and willing to perform pulmonary function tests (pft) and blood sampling for capillary blood gas analysis (po2, pco2) throughout the study, to keep a diary and to complete questionnaires exclusion criteria: * the patient requires invasive ventilation (non-invasive ventilation is allowed). * the patient uses non-invasive ventilation more than 16h/day. * the patient participates in another clinical study that involves therapy. * the patient cannot perform pulmonary function tests (pft). * the patient is diagnosed with central sleep apnea in polysomnography and not sufficiently treated with niv ventilation. * the patient is diagnosed with obstructive sleep apnea and not sufficiently treated with niv ventilation. * the patient cannot meet the requirements of the study, according to the investigator. * the patient is unable to complete a 6-minute walking test
study to evaluate the efficacy and safety of intravitreal otx-tki (ocular therapeutix) (axitinib implant) in subjects with neovascular age-related macular degeneration

Conditions: Neovascular Age-Related Macular Degeneration

Summary: study to evaluate the efficacy and safety of intravitreal otx-tki (axitinib implant) in subjects with neovascular age-related macular degeneration


Eligibility criteria:
inclusion criteria: * treatment naïve for neovascular age-related macular degeneration (namd) in either eye at screening. * are at least older than 50 years of age at day 1. * have best corrected visual acuity (bcva) of at least 84 early treatment diabetic retinopathy study (etdrs) letter score (approximate 20/20 snellen equivalent) at day 1; or have an increase of at least 10 etdrs letters of best corrected visual acuity (bcva) from screening (visit 1) bcva exclusion criteria: * monocular subjects or a best corrected visual acuity (bcva) score of 20/200 in fellow eye at screening. * have evidence of a scar, fibrosis, or atrophy of \> 50% of the total lesion in the study eye.

Keywords: neovascular age-related macular degeneration tyrosine kinase inhibitor otx-tki
internet-based interventions for cardiac arrest survivors

Conditions: Cognitive Impairment; Depression, Anxiety; Cardiac Arrest; Quality of Life; Social Functioning; Sexual Dysfunction

Summary: anxiety, depression and cognitive impairment symptoms are common among cardiac arrest survivors. this randomized clinical trial will test whether an internet-based lifestyle intervention administered through a web app can foster anxiety and depression symptoms in patients who survived an out-of-hospital cardiac arrest and suffer from these symptoms


Eligibility criteria:
inclusion criteria: * hospital discharge after out-of-hospital cardiac arrest with cerebral performance category 1 or 2 * hads anxiety or depression ≥ 8 and/or tics ≤ 31 * informed consent for participation in the study * native italian speaker or adequate understanding of the italian language * adequate ability to use the web to guarantee access to the contents exclusion criteria: * previous cognitive dysfunction * previous psychiatric disease * previous episode of out-of-hospital cardiac arrest
xenon-enhanced ventilation ct-guided radiotherapy for lung cancer treatment

Conditions: Lung Cancer; Radiation Therapy Complication

Summary: the investigators aim to use xenon-enhanced ventilation computed tomography (ct) to design personalized functional lung avoidance radiotherapy for lung cancer patients who are scheduled to receive lung radiation therapy. the investigators' goal is to optimally protect the lung function of the patients and reduce the incidence of radiation pneumonitis.

there has been an increase in the application of radiation therapy in the treatment of lung tumors; however, the associated side effect, called radiation pneumonitis, can significantly reduce lung function and the quality of life of patients, eventually leading to fatal consequences. the investigators aim to use xenon-enhanced ventilation computed tomography (ct) to design personalized functional lung avoidance radiotherapy for lung cancer patients who are scheduled to receive lung radiation therapy. the investigators' goal is to optimally protect the lung function of the patients and reduce the incidence of radiation pneumonitis.

Eligibility criteria:
inclusion criteria: * patients aged 20-80 years, with lung cancer receiving thoracic radiotherapy in ntuh, from february 2020 to december 2024. exclusion criteria: * the age is less than 20 years old or older than 80 years old. * unstable clinical condition, unable to maintain apnea for 15 second, and history of prior adverse reaction to xenon. * renal insufficiency patients. * claustrophobia * those who are pregnant.

Keywords: lung cancer radiation therapy xenon-enhanced ventilation ct
propranolol with standard chemoradiation for esophageal adenocarcinoma

Conditions: Esophageal Adenocarcinoma

Summary: this phase ii trial studies the side effects and best dose of propranolol when administered concurrently with soc neoadjuvant crt in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. patients who are already on β-blockers will receive standard of care crt and will be considered separately as a single arm prospective cohort

primary objective: i. to determine the safety and efficacy of propranolol hydrochloride (propranolol) in combination with standard neoadjuvant/definitive chemoradiation therapy (crt) for esophageal cancer. secondary objective: i. to estimate overall survival (os) and pathologic response rate in patients that undergo surgery.

Eligibility criteria:
inclusion criteria: * undergoing definitive or neoadjuvant crt for histologically confirmed esophageal adenocarcinoma * have an ecog performance status of 0-1 * have the ability to swallow and retain oral medication. if a patient is not able to swallow, they are still eligible for study provided they have an enteric feeding placed which will permit administration of crushed tablets or liquid formula propranolol prior to first radiation treatment * participants of child-bearing potential must have a negative pregnancy test at study entry and then agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. - should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * participant must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure. exclusion criteria: * contraindications to the use of beta-blockers, e.g.; uncontrolled depression, unstable angina pectoris, uncontrolled heart failure (new york heart association (nyha) grade iii or iv), hypotension ( systolic blood pressure \ 8.5 or fasting plasma glucose \> 160 mg/dl at screening), symptomatic peripheral arterial disease or raynaud's syndrome, untreated pheochromocytoma, current calcium channel blocker use (non-dihydropyridines such as verapamil) or rhythm control agents such as digoxin and amiodarone. patients with pacemakers will be excluded * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,symptomatic congestive heart failure, unstable angina pectoris, psychiatric illness/social situations that would limit compliance with study requirements, cardiac arrhythmia (atrial fibrillation/flutter), severe bradycardia (heart rate of \<50 beats per minute or 1st/ 2nd /3rd degree heart block) * pregnant or nursing female participants, * unwilling or unable to follow protocol requirements * any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug